Evidence map›Paper›PMID 36293142›Full record

ArticleInternational journal of molecular sciences2022

Magneto-Fluorescent Mesoporous Nanocarriers for the Dual-Delivery of Ofloxacin and Doxorubicin to Tackle Opportunistic Bacterial Infections in Colorectal Cancer.

Gonçalo A Marcelo, Joana Galhano, Tiago T Robalo, Maria Margarida Cruz, María D Marcos, Ramón Martínez-Máñez, Maria Paula Duarte, José Luis Capelo-Martínez, Carlos Lodeiro, Elisabete Oliveira

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Gonçalo A MarceloBIOSCOPE Group, LAQV@REQUIMTE, Chemistry Department, FCT NOVA, 2829-516 Caparica, Portugal.ORCID 0000-0003-1248-085X
Joana GalhanoBIOSCOPE Group, LAQV@REQUIMTE, Chemistry Department, FCT NOVA, 2829-516 Caparica, Portugal.ORCID 0000-0002-7149-1682
Tiago T RobaloBioISI-Instituto de Biosistemas e Ciências Integrativas, Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisboa, Portugal.
Maria Margarida CruzBioISI-Instituto de Biosistemas e Ciências Integrativas, Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisboa, Portugal.ORCID 0000-0001-8152-3054
María D MarcosInstituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico, Universitat Politècnica de València, Universitat de València, 46022 Valencia, Spain.ORCID 0000-0001-7079-8589
Ramón Martínez-MáñezInstituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico, Universitat Politècnica de València, Universitat de València, 46022 Valencia, Spain.ORCID 0000-0001-5873-9674
Maria Paula DuarteChemistry Department, FCT NOVA, 2829-516 Caparica, Portugal.
José Luis Capelo-MartínezBIOSCOPE Group, LAQV@REQUIMTE, Chemistry Department, FCT NOVA, 2829-516 Caparica, Portugal.ORCID 0000-0001-6276-8507
Carlos LodeiroBIOSCOPE Group, LAQV@REQUIMTE, Chemistry Department, FCT NOVA, 2829-516 Caparica, Portugal.ORCID 0000-0001-5582-5446
Elisabete OliveiraBIOSCOPE Group, LAQV@REQUIMTE, Chemistry Department, FCT NOVA, 2829-516 Caparica, Portugal.ORCID 0000-0002-8339-4820
Rede de Química e Tecnologia · PTUniversitat de València · ESUniversity of Lisbon · PTUniversidade Nova de Lisboa · PT

Funding

Fundação para a Ciência e Tecnologia PD/BD/142865/2018; CEECIND/00648/2017;Fundação para a Ciência e Tecnologia UIDB/04077/2020, UIDP/04077/2020; OrMagNa - PTDC/NAN-MAT/28785/2017, BioISI - UID/Multi/04046/2019, UIDB/04046/2020 and UIDP/04046/2020Fundação para a Ciência e Tecnologia UIDB/50006/2020 and UIDP/50006/2020Generalitat Valenciana Project PROMETEO 2018/024Ministerio de Ciencia e Innovación and FEDER Project RTI2018-100910-B-C41Proteomass Scientific Society General Funding Grant 2021
6 · The paper itself

Abstract

Cancer-related opportunistic bacterial infections are one major barrier for successful clinical therapies, often correlated to the production of genotoxic factors and higher cancer incidence. Although dual anticancer and antimicrobial therapies are a growing therapeutic fashion, they still fall short when it comes to specific delivery and local action in in vivo systems. Nanoparticles are seen as potential therapeutic vectors, be it by means of their intrinsic antibacterial properties and effective delivery capacity, or by means of their repeatedly reported modulation and maneuverability. Herein we report on the production of a biocompatible, antimicrobial magneto-fluorescent nanosystem (NANO3) for the delivery of a dual doxorubicin-ofloxacin formulation against cancer-related bacterial infections. The drug delivery capacity, rendered by its mesoporous silica matrix, is confirmed by the high loading capacity and stimuli-driven release of both drugs, with preference for tumor-like acidic media. The pH-dependent emission of its surface fluorescent SiQDs, provides an insight into NANO3 surface behavior and pore availability, with the SiQDs working as pore gates. Hyperthermia induces heat generation to febrile temperatures, doubling drug release. NANO3-loaded systems demonstrate significant antimicrobial activity, specifically after the application of hyperthermia conditions. NANO3 structure and antimicrobial properties confirm their potential use in a future dual anticancer and antimicrobial therapeutical vector, due to their drug loading capacity and their surface availability for further modification with bioactive, targeting species.

Indexed as

Anti-Infective AgentsColorectal NeoplasmsHyperthermia, InducedNanoparticlesAnti-Bacterial AgentsDoxorubicinDrug CarriersDrug Delivery SystemsDrug LiberationHumansOfloxacinPorositySilicon DioxideAnti-Bacterial AgentsAnti-Infective AgentsDoxorubicinDrug CarriersOfloxacinSilicon Dioxideantimicrobialdrug deliveryhyperthermiamagneto-fluorescencemesoporous nanoparticlesopportunistic cancer-related bacteria

Identifiers

PMID36293142
PMCPMC9603674
OpenAlexW4306385358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.